Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neurobo Pharmaceuticals Inc (NRBO)

Neurobo Pharmaceuticals Inc (NRBO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neurobo Pharmaceuticals Inc 545 Concord Avenue Suite 210 Cambridge MA 02138 USA

www.neurobopharma.com P: 857-702-9600

Description:

NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States.

Key Statistics

Overview:

Market Capitalization, $K 15,209
Enterprise Value, $K -7,231
Shares Outstanding, K 4,906
Annual Sales, $ 0 K
Annual Net Income, $ -12,470 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,310 K
EBIT, $ -15,890 K
EBITDA, $ -15,880 K
60-Month Beta -0.25
% of Insider Shareholders 0.79%
% of Institutional Shareholders 1.37%
Float, K 4,867
% Float 99.21%
Short Volume Ratio 0.31

Growth:

1-Year Return -42.41%
3-Year Return -99.64%
5-Year Return -99.96%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 99.98%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.72 on 11/13/23
Latest Earnings Date 05/10/24
Earnings Per Share ttm -1.36
EPS Growth vs. Prev Qtr -350.00%
EPS Growth vs. Prev Year 97.43%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 12/21/23

NRBO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -59.42%
Return-on-Assets % -45.40%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.91
Book Value/Share 3.44
Interest Coverage -28.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar